Basal, nutritional and correctional insulin dosing is based on SBGM (1). In type 1 diabetes (T1DM), frequent SBGM coupled with structured insulin titration improve glycemic control (2, 3).
Type 2 diabetes (T2DM) patients who are using multiple insulin injections also benefit from SBGM (4). However, T2DM patients who do not adjust their treatment (i.e. patients on diet alone, on oral agents, or on basal or premixed insulin injection) may not necessarily show significant improvement with SBGM. Based on these observations, the current guidelines recommend adult Type 1 DM patients monitor blood glucose at least twice a day, preferentially 6-10 times a day; before meals, at bedtime, occasionally after meals, before exercise, and before critical tasks such as driving (5). Recommendations for T2DM patients are different.
Those on oral hypoglycemic agents and/or basal insulin are asked to monitor blood glucose twice, at fasting and at bedtime. Patients using basal and pre-meal / pre-mixed insulin injections are guided to SBGM before meals and injections and before critical tasks (5). It is common in clinical practice that SBGM records do not correlate with patients' symptoms or HgBA1 results. For example, patients who present with the symptoms of hypoglycemia may not have documented low blood glucose on SBGM. Alternatively, HgBA1c may be much higher than what is expected from the SBGM recordings. This can happen even in those patients who follow the SBGM guidelines and instructions. In such cases continuous glucose monitoring 
Quality control measures for CGM:
The records are assessed for adequate information and optimal accuracy. Accuracy of the recordings is assessed by reviewing the CGM reports generated by the Medtronics -sitehttps://carelink.minimed.com/ipro/hcp/ which provides the mean absolute difference (MAD). This value expresses the average difference between the sensor and meter readings as percentage. The MAD values <28% is considered optimal (6).
Study protocol: Daily CGM recordings, each providing 288 glucose measures per 24 hours, were analyzed for four consecutive days. Data from the insertion and removal days were excluded as they were partial days and provided fewer than 288 measurements. The average MAD value (±SD) was 9.5±2.8 and no record was eliminated for having MAD > 28%. Self-blood glucose monitoring records from the same four days were also reviewed to determine the highest, the lowest and average glucose levels. The values (highest, lowest and average glucose) obtained by SBGM vs. CGM were compared. The time segments for the highest and lowest CGM-glucose were also recorded. HgbA1 results obtained within one month of the CGM measurements were used for correlations. 
Results
Clinical characteristics of the study subjects ( 38% of the highest blood glucose values were seen after dinner and in the evening; 17% after lunch, and 15% after breakfast. In T2DM, the highest glucose values were distributed evenly to the postprandial time segments: 20% after breakfast, 18% after lunch, and 28% after dinner and in the evening.
In T1DM, the lowest blood glucose values were seen during sleep (31%) and after dinner and in the evening (29%). In T2DM, the lowest blood glucose values were seen primarily during sleep (40%) and in the evening (14%).
Correlations between HgBA1c and the other variables (Table 3) : Both in T1DM and T2DM, HgBA1 correlated directly with the highest glucose and the average glucose measured by both by SBGM and CGM. HgBA1 also correlated directly with the lowest glucose value recorded by (8, 9) . In T2DM, carotid intimamedia thickness (10, 11) and coronary artery stenosis (12, 13) correlate with 2-h glucose levels during oral glucose tolerance test, independent of HgBA1. Moreover, anti-diabetic agents that target postprandial glucose can regress atherosclerotic disease, independent of the changes in HgBA1c (14). Diabetic retinopathy may also relate to postprandial glucose (15).
We observed that T1DM patients spent 7h/ day and T2DM spent 5.7 h/day with glucose levels above 200 mg/dl. Hyperglycemia occurred most frequently during the evening, and after meals.
These findings indicated the importance of postprandial glucose monitoring. The current recommendations are based on pre-meal glucose monitoring, in order to adjust the dose of the This study had several strengths: The instructions for SBGM were provided by the RN/CDE who was independent of the study and reflected the real-life situation. Patients were blinded to the CGM data, and they did not adjust their treatments based on the CGM. Four days of SBGM and CGM data were obtained simultaneously. Both T1DM and T2DM patients were included.
There were also weaknesses: Continuous glucose monitoring may have encouraged the patients to do more SBGM than they normally do, because of the three SBGMs required for calibration purposes. Hence, in daily practice, the discrepancy between CGM and SBGM may be wider.
In conclusion, this study demonstrated that CGM uncovers glucose patterns that common SBGM patterns can not; SBGM underestimates severity hyperglycemia as well as hypoglycemia. The highest CGM-glucose values are encountered during the post-prandial periods; and during the evening. The current guidelines which emphasize pre-meal SBGM miss the high glucose values occurring postprandially. Our findings make a strong case for SBGM after meals, especially in the evenings and in T2DM patients. Additional research is necessary to determine whether postprandial SBGM can improve overall glycemic control. 
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